SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Truist Securities BioPharma Symposium
Date: November 7, 2024
Location: Lotte New York Palace - New York, NY
Format: 1x1 meetings only

UBS Global Healthcare Conference
Date: November 13, 2024
Location: Rancho Palos Verdes, CA
Format: Fireside Chat
Time: 2:45 p.m. – 3:20 p.m. PT / 5:45 p.m. – 6:20 p.m. ET

Stifel 2024 Healthcare Conference
Date: November 18, 2024
Location: New York, NY
Format: Fireside Chat
Time: 9:10 a.m. – 9:40 a.m. ET

Jefferies London Healthcare Conference
Date: November 19-21, 2024
Location: London, UK
Format: 1x1 meetings only

Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at https://perspectivetherapeutics.com/investor-center.

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary ²¹²Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.